SURVYR

SBS

Companhia de Saneamento Básico do Estado de São Paulo - SABESP
$6.37
−$0.03 (0.47%)Oct 21 close
Utilities CompareTechnicals
1M3M6M1Y2Y
-8%+6%+20%+35%+49%Oct 2025Oct 2026Apr 202652w high $7.1652w low $4.45
SBSSPY
Wall St. Highest PT $7.60 (+19.3%) Wall St. Avg PT $6.66 (+4.6%)
$4$5$6$7$8POC $5Hi $8Avg $7
Underwater Drawdown %Max DD -37.0%Current -10.1%
0.0%-37.0%
Relative Strength vs SPY+15.8% vs SPYOutperforming
+48%0%-48%
1W
−$0.05 (0.78%)
1M
+$0.93 (17.10%)
3M
+$0.54 (9.26%)
6M
−$0.56 (8.05%)
YTD
+$1.63 (34.28%)
1Y
+$1.60 (33.50%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Analyst price targets
Current price$6.37
Average target$6.66
+$0.29 (+4.6%) upsideaverage target vs current price
CurrentAverageMedian
Low$6.28
Median$6.66
High$7.60
12-month Wall Street target range
Recent analyst rating changes · 9
Initiated
2026-03-19 · Jefferies started covering SBS at Buy
Initiated
2019-11-14 · Goldman Sachs started covering SBS at Neutral
Downgrade
2018-05-18 · Goldman Sachs downgraded SBS from Buy to Neutral
Downgrade
2018-03-12 · Janney Montgomery Scott downgraded SBS from Buy to Neutral
Upgrade
2017-11-27 · JP Morgan upgraded SBS from Neutral to Overweight
Upgrade
2017-11-22 · HSBC upgraded SBS from Hold to Buy
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$22.5B
P/E (last 12 months)14.2
P/E (next 12 months, estimated)14.8
52-week range$4.45 – $7.16
Revenue growth (latest quarter vs a year ago)+13.9%
Dividend yield0.52%
Average analyst price target$6.66 (+5%)

What they do

Companhia de Saneamento Básico do Estado de São Paulo - SABESP provides basic and environmental sanitation services in the São Paulo State, Brazil. It supplies treated water and sewage services on a wholesale basis. Companhia de Saneamento Básico do Estado de São Paulo - SABESP was founded in 1954 and is headquartered in São Paulo, Brazil.

Utilities · Utilities - Regulated Water
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for SBS yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

SBS earningsNext report in 8 days
Next report
Thu Nov 5, 2026Time not confirmed
EPS consensus$0.07 range $0.07–$0.07
Revenue consensus$6.1B 4 analysts
Last 4 quarters · EPS vs estimate
Aug 12, 2026$0.06est $0.08−24.0%Below estimates
May 7, 2026$0.09est $0.09+2.6%In line with estimates
Mar 15, 2026$0.11est $0.11−1.7%In line with estimates
Nov 10, 2025$0.07est $0.07−2.2%In line with estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-23 23:55:30 ET
24-1125-0325-0525-0825-1126-0326-0526-080.000.11
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$10.2B+13.9%
2026-03-31$10.0B–
2025-12-31$11.3B–
2025-09-30$9.4B–
2025-06-30$9.0B–

Recent dividends

2026-03-27: $0.032 · 2025-05-02: $0.131 · 2024-04-26: $0.056 · 2023-05-02: $0.051 · 2022-04-29: $0.040 · 2021-04-30: $0.014 · 2020-05-01: $0.050 · 2019-04-30: $0.060

News & catalysts

More news
Can SBS Holdings (TSE:2384) Justify Its Price With Cash Flow?
Simply Wall St. · Oct 20
Positive Preliminary Results Presented at Annual American College of Gastroenterology Meeting for Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer
ACCESS Newswire · Oct 14
SBS launches sovereign AI platform for core banking with NVIDIA
Retail Banker International · Oct 14
Preliminary Results of Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer Accepted for Presentation at Annual American College of Gastroenterology Meeting
ACCESS Newswire · Sep 29
Equatorial SA (EQUEY) (Q2 2026) Earnings Call Highlights: Strategic Expansion and Resilient ...
GuruFocus.com · Aug 14
Rating changes
Initiated
2026-03-19 · Jefferies started covering SBS at Buy
Initiated
2019-11-14 · Goldman Sachs started covering SBS at Neutral
Downgrade
2018-05-18 · Goldman Sachs downgraded SBS from Buy to Neutral
Downgrade
2018-03-12 · Janney Montgomery Scott downgraded SBS from Buy to Neutral
Upgrade
2017-11-27 · JP Morgan upgraded SBS from Neutral to Overweight
Upgrade
2017-11-22 · HSBC upgraded SBS from Hold to Buy

Third-party analyst actions, not SURVYR.'s views. All rating changes

Stats refreshed 2026-10-23 23:55:30 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026